Some Surprises in the European Commission’s New Intellectual Property Strategy

The European Commission's new intellectual property (IP) strategy is out and it holds a number of surprises for access to medicines. After restating the...

The new IP strategy of war-torn Ukraine should prioritise public health and national security

Russia’s full-scale assault on Ukraine continues for the third year. The Russian occupation forces have already killed tens of thousands of civilians, including children. They have...

WHO Fair Pricing Forum: Watching for Drug Industry Accountability

by Katrina Perehudoff and Jennifer Sellin Expensive medicines are a ubiquitous challenge from which no government is immune. Excessive price hikes are an urgent human...

Gilead’s sofosbuvir patent in India – options for global access to new hepatitis C...

Earlier this month the US pharmaceutical company Gilead obtained a patent in India for sofosbuvir, part of a treatment of hepatitis C that became...

The world needs a signal that multilateralism works: ML&P opening statement to the INB13,...

Thank you for the opportunity to make a brief statement. The negotiations for the Pandemic Agreement enter the final phase. We hope and wish for...

A better way to solve a crisis: A new mechanism for incentivising R&D on...

Antimicrobial resistance is the ‘silent’ pandemic: Globally, it costs 5 million lives a year, and is set to rise to more than 8 million...
Cherry blossom

The Pandemic Agreement is here

In December 2021, the member states of the World Health Organization decided “to draft and negotiate a WHO convention, agreement or other international instrument...

World Health Organization Members ask for more time to solve difficult negotiations on access...

World Health Organization member states will propose to continue negotiations on a critical annex to the Pandemic Agreement, after being unable to bridge key...

Commission report on competition enforcement in the pharmaceutical sector

Guest author Jacquelyn D. Veraldi is Assistant Professor of European Law at the University of Groningen. Guest author Tais A. Ruiz Palacios is a...

The Italian Exception – A personalised approach to accessing high-priced patented medicines

At the end of March 2017, the Italian Minister of Health Beatrice Lorenzin has authorised the importation of generic medicines. She did this with...